CA3087009A1 - Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation - Google Patents

Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation Download PDF

Info

Publication number
CA3087009A1
CA3087009A1 CA3087009A CA3087009A CA3087009A1 CA 3087009 A1 CA3087009 A1 CA 3087009A1 CA 3087009 A CA3087009 A CA 3087009A CA 3087009 A CA3087009 A CA 3087009A CA 3087009 A1 CA3087009 A1 CA 3087009A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
cycloalkyl
substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087009A
Other languages
English (en)
French (fr)
Inventor
Sumayah Jamal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enb Therapeutics Inc
Original Assignee
Enb Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enb Therapeutics Inc filed Critical Enb Therapeutics Inc
Publication of CA3087009A1 publication Critical patent/CA3087009A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3087009A 2018-01-12 2019-01-11 Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation Pending CA3087009A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616729P 2018-01-12 2018-01-12
US62/616,729 2018-01-12
PCT/US2019/013377 WO2019140324A1 (en) 2018-01-12 2019-01-11 Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Publications (1)

Publication Number Publication Date
CA3087009A1 true CA3087009A1 (en) 2019-07-18

Family

ID=67212721

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087009A Pending CA3087009A1 (en) 2018-01-12 2019-01-11 Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation

Country Status (10)

Country Link
US (4) US10435434B2 (https=)
EP (1) EP3713571A4 (https=)
JP (1) JP7539151B2 (https=)
KR (1) KR102846292B1 (https=)
CN (1) CN111886010A (https=)
AU (1) AU2019206652B2 (https=)
CA (1) CA3087009A1 (https=)
EA (1) EA202091630A1 (https=)
MX (1) MX2020007293A (https=)
WO (1) WO2019140324A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695400B2 (en) 2015-08-03 2020-06-30 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
AU2019206652B2 (en) * 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
CN114423425A (zh) * 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
TW202120486A (zh) * 2019-08-09 2021-06-01 英商阿帝歐斯製藥有限公司 新穎化合物
EP4608447A1 (en) * 2022-10-28 2025-09-03 ENB Therapeutics, Inc. Methods for treating cancers associated with etbr activation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4874780A (en) * 1987-03-11 1989-10-17 Norsk Hydro A.S. Anticancer compounds
US5496928A (en) 1990-06-07 1996-03-05 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
TW217417B (https=) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
EP0991660B8 (en) 1997-10-08 2006-04-05 Isotechnika,Inc. DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006019637A2 (en) 2004-07-07 2006-02-23 The Regents Of The University An intelligent nanomedicine integrating diagnosis and therapy
US20080102451A1 (en) 2006-10-31 2008-05-01 Abbott Laboratories Companion diagnostic assays for endothelin receptor antagonists
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US9289426B2 (en) 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
US8303974B2 (en) 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
CN102170908A (zh) 2008-08-29 2011-08-31 莱顿大学医学中心附属莱顿教学医院 向个体的肿瘤引流淋巴结递送cd40激动剂
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
ES2543280T3 (es) 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
US20140341916A1 (en) 2011-10-28 2014-11-20 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US10233277B2 (en) 2012-03-02 2019-03-19 The Governing Council Of The University Of Toronto Polymeric nanoparticles useful in theranostics
WO2014025837A1 (en) 2012-08-06 2014-02-13 Board Of Regents, The University Of Texas System Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
WO2015110593A1 (en) 2014-01-24 2015-07-30 Cecilia Naucler Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RS61152B2 (sr) 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
JP7144935B2 (ja) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
US10695400B2 (en) 2015-08-03 2020-06-30 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
EP3746110A4 (en) 2018-03-30 2022-03-02 ENB Therapeutics, Inc. ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS AND USES
CN114423425A (zh) 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌
US20200289495A1 (en) 2020-03-24 2020-09-17 Enb Therapeutics, Inc. Methods of inhibiting endothelin b receptor expressing tumor metastases
US20200268829A1 (en) 2020-03-24 2020-08-27 Enb Therapeutics, Inc. Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer

Also Published As

Publication number Publication date
US20190218251A1 (en) 2019-07-18
US12077604B2 (en) 2024-09-03
JP2021510680A (ja) 2021-04-30
JP7539151B2 (ja) 2024-08-23
US20190345197A1 (en) 2019-11-14
KR102846292B1 (ko) 2025-08-13
US11066442B2 (en) 2021-07-20
MX2020007293A (es) 2021-01-08
EP3713571A1 (en) 2020-09-30
WO2019140324A1 (en) 2019-07-18
US10435434B2 (en) 2019-10-08
US20240360173A1 (en) 2024-10-31
US20210309694A1 (en) 2021-10-07
EA202091630A1 (ru) 2020-12-04
KR20200119246A (ko) 2020-10-19
CN111886010A (zh) 2020-11-03
AU2019206652A1 (en) 2020-07-16
EP3713571A4 (en) 2021-08-25
AU2019206652B2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
US12485120B2 (en) Methods of treating disorders using CSF1R inhibitors
US12077604B2 (en) Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US20210077562A1 (en) Etbr antagonist compounds, compositions, and uses
EP3331542A2 (en) Compositions and methods for treating cancers associated with etbr activation
US20220265628A1 (en) Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
WO2021178789A1 (en) Methods of using rebastinib in the treatment of different cancerous disorders
EA046650B1 (ru) Дейтерированные соединения, композиции и способы для лечения рака, связанного с активацией etbr

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20251003

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260407